Epidemiology and pathophysiology of cancer-associated thrombosis.
Venous thromboembolism (VTE) is a common complication in patients with malignant disease. First recognised by Bouillard in 1823 and later described by Trousseau in 1844, multiple studies have since provided considerable evidence for a clinical association between VTE and cancer. Across all cancers, the risk for VTE is elevated 7-fold; in certain malignancies, the risk for VTE may be increased up to 28-fold. Venous thromboembolism is the second leading cause of death in patients with cancer; among survivors, complications commonly include recurrent VTE and post-thrombotic syndrome, and (more rarely) chronic thromboembolic pulmonary hypertension, which are costly, and have a profound impact on the patient's quality of life. Tumour cells can activate blood coagulation through multiple mechanisms, including production of procoagulant, fibrinolytic, and proaggregating activities, release of proinflammatory and proangiogenic cytokines, and interacting directly with host vascular and blood cells (e.g., endothelial cells, leukocytes, and platelets) through adhesion molecules. Increasing evidence suggests that elements of the haemostatic system also have a direct role in eliciting or enhancing angiogenesis, cell survival, and metastasis. Despite the problem posed by VTE in the setting of cancer, it is evident that a significant number of oncologists do not recognise the link between cancer, its treatment, and thrombogenesis. On 22 May 2009, a group of UK-based physicians met in London, UK, to evaluate recent data on cancer thrombosis. This article (1 of 4) briefly reviews key data on the epidemiology and pathophysiology of VTE as a context for a discussion and consensus statement developed by meeting attendees, on the implications of this information for UK clinical practice.
Noble
S
S
Royal Gwent Hospital, Cardiff Road, Newport NP202UB, UK. simon.noble@gwent.wales.nhs.uk
Pasi
J
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D006487:Hemostasis; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D011655:Pulmonary Embolism / Q000209:etiology; D012008:Recurrence; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology*
D020533:Angiogenesis Inhibitors; D013629:Tamoxifen
JAMA. 2008 Nov 19;300(19):2277-85
19017914
N Engl J Med. 2004 May 27;350(22):2257-64
15163775
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Lancet Oncol. 2005 Jun;6(6):401-10
15925818
Blood. 2001 Jul 15;98(2):492-4
11435324
Medicine (Baltimore). 1999 Sep;78(5):285-91
10499070
Arch Intern Med. 1997 Jan 13;157(1):57-62
8996041
J Thromb Haemost. 2004 Dec;2(12):2107-14
15613014
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
JAMA. 2005 Feb 9;293(6):715-22
15701913
Lancet. 2005 Jan 1-7;365(9453):60-2
15639680
J Clin Oncol. 2003 Oct 1;21(19):3665-75
14512399
Thromb Haemost. 1994 Oct;72(4):548-50
7878630
Am J Med. 2006 Jan;119(1):60-8
16431186
J Thromb Haemost. 2004 Oct;2(10):1760-5
15456487
Arch Intern Med. 2005 Aug 8-22;165(15):1782-7
16087828
J Clin Oncol. 1991 Feb;9(2):286-94
1988575
Haematologica. 1997 Jul-Aug;82(4):423-8
9299855
J Exp Med. 2006 Mar 20;203(3):493-5
16533890
Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):47-56
15569823
Oncologist. 2003;8(4):381-8
12897335
Semin Thromb Hemost. 2004 Feb;30(1):31-44
15034796
Blood Rev. 2001 Jun;15(2):61-7
11409906
Blood. 2001 Sep 1;98(5):1614-5
11520815
Biochemistry. 1985 Sep 24;24(20):5558-67
3935163
Ann Surg. 2006 Jan;243(1):89-95
16371741
Blood. 2002 Sep 15;100(6):2272-3
12229885
Cancer Lett. 1999 Nov 1;146(1):61-6
10656610
J Clin Oncol. 2006 Jan 20;24(3):484-90
16421425
Lancet. 1995 Oct 14;346(8981):1004-5
7475548
Semin Thromb Hemost. 2008 Mar;34(2):143-5
18645918
Blood. 2002 Nov 15;100(10):3484-8
12393647
J Immunol. 1995 Jul 15;155(2):867-76
7608564
BMJ. 2003 Sep 13;327(7415):597-8
12969928
J Natl Cancer Inst. 2006 May 17;98(10):708-14
16705125
Br J Cancer. 2004 Jul 5;91(1):92-5
15226761
Cancer Res. 1999 May 1;59(9):2244-50
10232615
J Clin Oncol. 2005 Apr 10;23(11):2574-6
15795413